# BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

> **NCT03944356** · — · COMPLETED · sponsor: **EuMelaReg gGmbH** · enrollment: 232 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Dabrafenib and Trametinib

## Key facts

- **NCT ID:** NCT03944356
- **Lead sponsor:** EuMelaReg gGmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-10-08
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03944356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03944356, "BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03944356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*